-
1
-
-
0024832082
-
Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2
-
Maas RA, Dullens HF, De Jong WH, Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 1989; 49(24 Pt 1): 7037-7040
-
(1989)
Cancer Res.
, vol.49
, Issue.24 PART 1
, pp. 7037-7040
-
-
Maas, R.A.1
Dullens, H.F.2
De Jong, W.H.3
Den Otter, W.4
-
2
-
-
2342530941
-
Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma
-
Kusnierczyk H, Pajtasz Piasecka E, Koten JW, Bijleveld C, Krawczyk K, Den Otter W. Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 2004; 53: 445-452
-
(2004)
Cancer Immunol. Immunother.
, vol.53
, pp. 445-452
-
-
Kusnierczyk, H.1
Pajtasz Piasecka, E.2
Koten, J.W.3
Bijleveld, C.4
Krawczyk, K.5
Den Otter, W.6
-
3
-
-
0027176104
-
Locoregional therapy with polyethyleneglycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pigs induces T-cell-mediated antitumour activity
-
Balemans LTM, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PHM, Den Otter W. Locoregional therapy with polyethyleneglycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pigs induces T-cell-mediated antitumour activity. Cancer Immunol Immunother 1993; 37: 7
-
(1993)
Cancer Immunol. Immunother.
, vol.37
, pp. 7
-
-
Balemans, L.T.M.1
Mattijssen, V.2
Steerenberg, P.A.3
Van Driel, B.E.4
De Mulder, P.H.M.5
Den Otter, W.6
-
4
-
-
0027842747
-
Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma
-
Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rutten VP, Ruitenberg EJ. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 1993; 13: 2453-2455
-
(1993)
Anticancer Res.
, vol.13
, pp. 2453-2455
-
-
Den Otter, W.1
Hill, F.W.2
Klein, W.R.3
Koten, J.W.4
Steerenberg, P.A.5
De Mulder, P.H.6
Rutten, V.P.7
Ruitenberg, E.J.8
-
5
-
-
0029127881
-
Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 mo of follow-up
-
Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Faber JAJ, Ruitenberg EJ, Rutten VPMG Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 mo of follow-up. Cancer Immunol Immunother 1995; 41: 10
-
(1995)
Cancer Immunol. Immunother.
, vol.41
, pp. 10
-
-
Den Otter, W.1
Hill, F.W.G.2
Klein, W.R.3
Koten, J.W.4
Steerenberg, P.A.5
De Mulder, P.H.M.6
Rhode, C.7
Faber, J.A.J.8
Ruitenberg, E.J.9
Rutten, V.P.M.G.10
-
6
-
-
0037382915
-
Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or Cisplatin/IL-2
-
Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or Cisplatin/IL-2. Cancer Immunol Immunother 2003; 52: 179-184
-
(2003)
Cancer Immunol. Immunother.
, vol.52
, pp. 179-184
-
-
Spoormakers, T.J.1
Klein, W.R.2
Jacobs, J.J.3
Van Den Ingh, T.S.4
Koten, J.W.5
Den Otter, W.6
-
7
-
-
0031897859
-
Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 out of 10 patients
-
Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 out of 10 patients. J Urol 1998; 159: 1183
-
(1998)
J. Urol.
, vol.159
, pp. 1183
-
-
Den Otter, W.1
Dobrowolski, Z.2
Bugajski, A.3
Papla, B.4
Van der Meijden, A.P.M.5
Koten, J.W.6
Boon, T.A.7
Siedlar, M.8
Zembala, M.9
-
8
-
-
0021217020
-
Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer
-
Pizza G, Severini G, Menniti D, De Vinci C, Corrado F. Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int J Cancer 1984; 34: 359-367
-
(1984)
Int. J. Cancer
, vol.34
, pp. 359-367
-
-
Pizza, G.1
Severini, G.2
Menniti, D.3
De Vinci, C.4
Corrado, F.5
-
9
-
-
22144471231
-
Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low dose of IL-2
-
Jacobs JJ, Hordijk GJ, Jurgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ, Den Otter W. Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low dose of IL-2. Cancer Immunol Immunother 2005; 54: 792-798
-
(2005)
Cancer Immunol. Immunother.
, vol.54
, pp. 792-798
-
-
Jacobs, J.J.1
Hordijk, G.J.2
Jurgenliemk-Schulz, I.M.3
Terhaard, C.H.4
Koten, J.W.5
Battermann, J.J.6
Den Otter, W.7
-
10
-
-
0032781576
-
Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)
-
Huland E, Heinzer H, Huland H. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res 1999; 19: 2679
-
(1999)
Anticancer Res.
, vol.19
, pp. 2679
-
-
Huland, E.1
Heinzer, H.2
Huland, H.3
-
11
-
-
9344221642
-
Optimal regimes for local IL-2 tumour therapy
-
Den Otter W, De Groot JW, Bernsen MR, Heintz APM, Maas R, Hordijk GJ, Hill FWG, Klein WR, Ruitenberg EJ, Rutten VPMG. Optimal regimes for local IL-2 tumour therapy. Int J Cancer 1996; 88: 400
-
(1996)
Int. J. Cancer
, vol.88
, pp. 400
-
-
Den Otter, W.1
De Groot, J.W.2
Bernsen, M.R.3
Heintz, A.P.M.4
Maas, R.5
Hordijk, G.J.6
Hill, F.W.G.7
Klein, W.R.8
Ruitenberg, E.J.9
Rutten, V.P.M.G.10
-
12
-
-
0036387498
-
The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy
-
Baselmans AHC, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 2002; 51: 492
-
(2002)
Cancer Immunol. Immunother.
, vol.51
, pp. 492
-
-
Baselmans, A.H.C.1
Koten, J.W.2
Battermann, J.J.3
Van Dijk, J.E.4
Den Otter, W.5
-
13
-
-
21244457998
-
Local Interleukin-2 therapy is therapeutically most effective against cancer when injected intratumorally
-
Jacobs JJ, Sparendam D, Den Otter W. Local Interleukin-2 therapy is therapeutically most effective against cancer when injected intratumorally. Cancer Immunol Immunother 2005; 54: 647-654
-
(2005)
Cancer Immunol. Immunother.
, vol.54
, pp. 647-654
-
-
Jacobs, J.J.1
Sparendam, D.2
Den Otter, W.3
-
14
-
-
0027965586
-
PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumour and beneficial effect of cyclophosphamide
-
Balemans LTM, Steerenberg PA, Koppenhagen FJ, Kremer BRA, De Mulder PHM, Claessen AME, Scheper RJ, Den Otter W. PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumour and beneficial effect of cyclophosphamide. Int J Cancer 1994; 58: 871
-
(1994)
Int. J. Cancer
, vol.58
, pp. 871
-
-
Balemans, L.T.M.1
Steerenberg, P.A.2
Koppenhagen, F.J.3
Kremer, B.R.A.4
De Mulder, P.H.M.5
Claessen, A.M.E.6
Scheper, R.J.7
Den Otter, W.8
-
15
-
-
0034480084
-
Perilesional IL-2 treatment of a VX2 head and neck cancer model can induce a systemic antitumor activity
-
Van Es RJJ, Baselmans AHC, Van Dijk JE, Koole R, Den Otter W. Perilesional IL-2 treatment of a VX2 head and neck cancer model can induce a systemic antitumor activity. Anticancer Res 2000; 20: 4163
-
(2000)
Anticancer Res.
, vol.20
, pp. 4163
-
-
Van Es, R.J.J.1
Baselmans, A.H.C.2
Van Dijk, J.E.3
Koole, R.4
Den Otter, W.5
-
16
-
-
0141650696
-
A case of hepatocellular carcinoma (HCC): Treatment with local application of alcohol and interleukin-2 (IL-2)
-
Krastev Z, Koltchakov V, Popov D, Alexiev A, Koten JW, Den Otter W. A case of hepatocellular carcinoma (HCC): Treatment with local application of alcohol and interleukin-2 (IL-2). Hepatogastroenterology 2003; 50: 1647
-
(2003)
Hepatogastroenterology
, vol.50
, pp. 1647
-
-
Krastev, Z.1
Koltchakov, V.2
Popov, D.3
Alexiev, A.4
Koten, J.W.5
Den Otter, W.6
-
17
-
-
0034918404
-
A mesothelioma that is sensitive to locally applied IL-2
-
Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W. A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 2001; 50: 226
-
(2001)
Cancer Immunol. Immunother.
, vol.50
, pp. 226
-
-
Krastev, Z.1
Koltchakov, V.2
Vladov, N.3
Popov, D.4
Milev, A.5
Koten, J.W.6
Den Otter, W.7
-
18
-
-
0031916221
-
Interleukin-2: Hope in case of Cisplatin resistant tumors
-
Bernsen MR, Van der Velden D, Everse LA, Dullens HFJ, Den Otter W, Heintz APM. Interleukin-2: Hope in case of Cisplatin resistant tumors. Cancer Immunol Immunother 1998; 46: 41
-
(1998)
Cancer Immunol. Immunother.
, vol.46
, pp. 41
-
-
Bernsen, M.R.1
Van der Velden, D.2
Everse, L.A.3
Dullens, H.F.J.4
Den Otter, W.5
Heintz, A.P.M.6
-
19
-
-
0030816494
-
Local low dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A preclinical study
-
Everse LA, Renes IB, Jürgenliempk-Schultz IM, Rutgers DH, Bernsen MR, Dullens HFJ, Den Otter W, Battermann JJ. Local low dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A preclinical study. Int J Cancer 1997; 72: 1003
-
(1997)
Int. J. Cancer
, vol.72
, pp. 1003
-
-
Everse, L.A.1
Renes, I.B.2
Jürgenliempk-Schultz, I.M.3
Rutgers, D.H.4
Bernsen, M.R.5
Dullens, H.F.J.6
Den Otter, W.7
Battermann, J.J.8
-
20
-
-
17844380760
-
Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin 2
-
Lissoni P, Mandala M, Curigliano G, Ferretti G, Moro C, Arddizoia A, Malugani F, Tancini G, Tisi E, Arrigoni C, Barni S. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin 2. Oncology 2001; 60: 308
-
(2001)
Oncology
, vol.60
, pp. 308
-
-
Lissoni, P.1
Mandala, M.2
Curigliano, G.3
Ferretti, G.4
Moro, C.5
Arddizoia, A.6
Malugani, F.7
Tancini, G.8
Tisi, E.9
Arrigoni, C.10
Barni, S.11
|